Median Arcuate Ligament Syndrome: Treatment | AETNA Coverage Update

Summary: Aetna modified CPB 1092, its coverage policy for Median Arcuate Ligament Syndrome treatment, with an effective date of 2026-05-08. Here's what billing teams need to know before claims start hitting the wall.

Aetna, a CVS Health company, updated CPB 1092 governing its Median Arcuate Ligament Syndrome (MALS) coverage policy. This condition sits at the intersection of vascular surgery, gastroenterology, and interventional radiology — which means multiple specialties are billing into this policy simultaneously, and a modification here creates ripple effects across several service lines. The updated policy does not list specific CPT, HCPCS, or ICD-10 codes in the data provided for this change, so we'll address the clinical and billing framework in full below. If you bill for MALS workup, diagnosis, or surgical decompression under Aetna, read this before May 8, 2026.

Quick-Reference Table

Aetna Median Arcuate Ligament Syndrome Coverage Criteria and Medical Necessity Requirements 2026

Median Arcuate Ligament Syndrome is a rare condition. The median arcuate ligament — a fibrous arch connecting the diaphragm's left and right crura — compresses the celiac artery. That compression causes chronic postprandial abdominal pain, weight loss, and a vascular bruit. Because those symptoms overlap with a dozen other conditions, Aetna scrutinizes MALS claims hard. The medical necessity bar is high, and it's not getting lower.

The core problem in Median Arcuate Ligament Syndrome billing is that this condition is chronically under-documented at the claim level. Imaging findings, symptom duration, and failed conservative management all play into the coverage determination. Aetna's CPB 1092 Aetna system has historically required a documented clinical workup — duplex ultrasound, CT angiography, or MRA showing celiac artery compression — before surgical or interventional treatment gets covered.

For a claim to clear medical necessity under this coverage policy, the clinical record typically needs to show a confirmed anatomical finding of celiac axis compression. That means imaging evidence isn't optional — it's the threshold. Without it, Aetna will deny surgical decompression as not medically necessary, regardless of symptom severity.

Prior authorization is almost certainly required for the surgical procedure — median arcuate ligament release, typically performed laparoscopically or robotically. Do not submit a claim for MALS decompression surgery without checking prior authorization status first. Retroactive authorization for this procedure class is nearly impossible to get after the fact, and a claim denial at that dollar amount is a serious revenue hit.

The updated CPB 1092 may also clarify — or tighten — the criteria around adjunctive procedures. Celiac plexus neurolysis and revascularization after decompression have historically existed in a gray zone under this policy. If your practice performs these as part of a MALS surgical episode, audit those components separately. They may carry different medical necessity documentation requirements than the decompression itself.

Aetna MALS Treatment Exclusions and Non-Covered Indications

MALS treatment has always had a contested experimental zone, and CPB 1092 reflects that. Treatments that lack consistent long-term outcome data are the most likely targets for an "experimental or investigational" designation under Aetna's framework.

Celiac plexus block — used in some practices as a diagnostic or therapeutic step — sits in uncertain territory under this policy. If your pain management team is billing for celiac blocks as part of a MALS workup or treatment protocol, check the updated CPB 1092 carefully. Aetna has historically been skeptical of standalone celiac interventions for MALS without a clear pathway to surgical correction.

Endovascular stenting of the celiac artery for MALS — as opposed to open or laparoscopic ligament release — is another area that carries elevated denial risk. The surgical standard for MALS is decompression, not stenting. If a patient received stenting as a primary MALS treatment, expect Aetna to scrutinize that claim under the experimental designation. Document the clinical rationale thoroughly if your physician chose stenting.

Robotic-assisted approaches to MALS decompression have expanded in recent years. Whether CPB 1092's modification addresses robotic-specific billing isn't confirmed in the data available here. Talk to your compliance officer about how your facility codes robotic MALS decompression before the effective date of May 8, 2026.

Coverage Indications at a Glance

Because the policy data for CPB 1092 does not include a specific code-level breakdown, the table below reflects the known clinical framework for MALS coverage under Aetna's general policy structure. Verify each indication against the full updated CPB 1092 text at Aetna's clinical policy library.

This table is based on the known Aetna MALS policy framework. The updated CPB 1092 may change specific coverage statuses. Confirm against the full policy text before billing.

Aetna MALS Treatment Billing Guidelines and Action Items 2026

The effective date is May 8, 2026. That's your hard deadline for updating workflows. Here's what to do now.

CPT, HCPCS, and ICD-10 Codes for MALS Treatment Under CPB 1092

The policy data provided for this change does not include specific CPT, HCPCS, or ICD-10 codes. Aetna's clinical policy bulletins sometimes reference codes in supporting appendices rather than the main policy body.

Do not invent or assume codes based on the procedure type alone. Median Arcuate Ligament Syndrome billing involves several possible procedure codes depending on surgical approach (open vs. laparoscopic vs. robotic) and adjunctive procedures performed. Using the wrong code — even a plausible one — on an Aetna claim is a claim denial and potentially a compliance exposure.

Action: Access the full CPB 1092 updated policy text directly from Aetna's provider portal or request the applicable code list from your Aetna provider relations contact before May 8, 2026. Cross-reference any codes you identify against your current charge master to confirm alignment with the updated coverage policy.